

FILE 'HOME' ENTERED AT 15:51:43 ON 17 FEB 2004

=> file medicine bioscience

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'ADISCTI' ENTERED AT 15:52:03 ON 17 FEB 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 15:52:03 ON 17 FEB 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 15:52:03 ON 17 FEB 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'BIOSIS' ENTERED AT 15:52:03 ON 17 FEB 2004

COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHNO' ENTERED AT 15:52:03 ON 17 FEB 2004

COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CANCERLIT' ENTERED AT 15:52:03 ON 17 FEB 2004

FILE 'CAPLUS' ENTERED AT 15:52:03 ON 17 FEB 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEN' ENTERED AT 15:52:03 ON 17 FEB 2004

COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'DISSABS' ENTERED AT 15:52:03 ON 17 FEB 2004

COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 15:52:03 ON 17 FEB 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 15:52:03 ON 17 FEB 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGMONOG2' ENTERED AT 15:52:03 ON 17 FEB 2004

COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 15:52:03 ON 17 FEB 2004

COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 15:52:03 ON 17 FEB 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBAL' ENTERED AT 15:52:03 ON 17 FEB 2004

COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 15:52:03 ON 17 FEB 2004

COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 15:52:03 ON 17 FEB 2004

COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'IFIPAT' ENTERED AT 15:52:03 ON 17 FEB 2004

COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IPA' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 American Society of Hospital Pharmacists (ASHP)

FILE 'JICST-EPLUS' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 15:52:03 ON 17 FEB 2004

FILE 'NAPRALERT' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 Board of Trustees of the University of Illinois,  
University of Illinois at Chicago.

FILE 'NLDB' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'NUTRACEUT' ENTERED AT 15:52:03 ON 17 FEB 2004  
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PASCAL' ENTERED AT 15:52:03 ON 17 FEB 2004  
Any reproduction or dissemination in part or in full,  
by means of any process and on any support whatsoever  
is prohibited without the prior written agreement of INIST-CNRS.  
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 WIPO

FILE 'PHARMAML' ENTERED AT 15:52:03 ON 17 FEB 2004  
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'SCISEARCH' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT 2004 THOMSON ISI

FILE 'TOXCENTER' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 15:52:03 ON 17 FEB 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:52:03 ON 17 FEB 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'AGRICOLA' ENTERED AT 15:52:03 ON 17 FEB 2004

FILE 'ANABSTR' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUASCI' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'CABA' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CEABA-VTB' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CIN' ENTERED AT 15:52:03 ON 17 FEB 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'IMSRESEARCH' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'FEDRIP' ENTERED AT 15:52:03 ON 17 FEB 2004

FILE 'FOMAD' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 15:52:03 ON 17 FEB 2004

FILE 'HEALSAFE' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'NIOSHTIC' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 15:52:03 ON 17 FEB 2004  
Compiled and distributed by the NTIS, U.S. Department of Commerce.  
It contains copyrighted material.  
All rights reserved. (2004)

FILE 'OCEAN' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PHAR' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'RDISCLOSURE' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SYNTHLINE' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 Prous Science

FILE 'VETB' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'VETU' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIDS' ENTERED AT 15:52:03 ON 17 FEB 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s (GLP-1 OR GLUCAGON (W) LIKE (W) PEPTIDE (W) 1) (S) (INTERMITTENT (w) CLAUDICATION)  
AND (PERIPHERAL (W) VASCULAR (W) DISEASE)

L1	0	FILE ADISCTI
L2	0	FILE ADISINSIGHT
L3	0	FILE ADISNEWS
L4	0	FILE BIOSIS
L5	0	FILE BIOTECHNO
L6	0	FILE CANCERLIT
L7	1	FILE CAPLUS
L8	0	FILE 'CEN
L9	0	FILE DISSABS
L10	13	FILE DGENE
L11	0	FILE DRUGB
L12	0	FILE DRUGMONOG2
L13	0	FILE IMSDRUGNEWS
L14	0	FILE DRUGU
L15	0	FILE EMBAL
L16	0	FILE EMBASE
L17	0	FILE ESBIODBASE
L18	1	FILE IFIPAT
L19	0	FILE IMSPRODUCT
L20	0	FILE IPA
L21	0	FILE JICST-EPLUS
L22	0	FILE KOSMET
L23	0	FILE LIFESCI
L24	0	FILE MEDICONF
L25	0	FILE MEDLINE
L26	0	FILE NAPRALERT
L27	0	FILE NLDB
L28	0	FILE NUTRACEUT
L29	0	FILE PASCAL
L30	0	FILE PCTGEN
L31	0	FILE PHARMAML
L32	0	FILE PHIC
L33	0	FILE PHIN
L34	0	FILE SCISEARCH
L35	0	FILE TOXCENTER
L36	1	FILE USPATFULL

L37 0 FILE USPAT2  
 L38 0 FILE AGRICOLA  
 L39 0 FILE ANABSTR  
 L40 0 FILE AQUASCI  
 L41 0 FILE BIOBUSINESS  
 L42 0 FILE BIOCOMMERCE  
 L43 0 FILE BIOTECHDS  
 L44 0 FILE CABA  
 L45 0 FILE CEABA-VTB  
 L46 0 FILE CIN  
 L47 0 FILE CONFSCI  
 L48 0 FILE CROPB  
 L49 0 FILE CROPU  
 L50 0 FILE IMSRESEARCH

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
 FIELD CODE - 'AND' OPERATOR ASSUMED '1) (S) '

L51 0 FILE FEDRIP  
 L52 0 FILE FOMAD  
 L53 0 FILE FOREGE  
 L54 0 FILE FROSTI  
 L55 0 FILE FSTA  
 L56 0 FILE GENBANK  
 L57 0 FILE HEALSAFE  
 L58 0 FILE NIOSHTIC  
 L59 0 FILE NTIS  
 L60 0 FILE OCEAN  
 L61 0 FILE PHAR  
 L62 0 FILE PROMT  
 L63 0 FILE RDISCLOSURE  
 L64 0 FILE SYNTHLINE  
 L65 0 FILE VETB  
 L66 0 FILE VETU  
 L67 1 FILE WPIDS

TOTAL FOR ALL FILES

L68 17 (GLP-1 OR GLUCAGON (W) LIKE (W) PEPTIDE (W) 1) (S) (INTERMITTENT  
 (W) CLAUDICATION) AND (PERIPHERAL (W) VASCULAR (W) DISEASE)

=> dup rem l68

DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DGENE, DRUGMONOG2,  
 IMSPRODUCT, KOSMET, MEDICONF, NUTRACEUT, PCTGEN, PHARMAML, BIOCOMMERCE,  
 IMSRESEARCH, FEDRIP, FOREGE, GENBANK, PHAR, RDISCLOSURE, SYNTHLINE'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

PROCESSING COMPLETED FOR L68

L69 14 DUP REM L68 (3 DUPLICATES REMOVED)

=> d l69 1-4 ibib abs

L69 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2003:300601 CAPLUS

DOCUMENT NUMBER: 138:298126

TITLE: Compositions and methods for treating  
**peripheral vascular disease**  
 with GLP-1 compounds

INVENTOR(S): Hathaway, David R.; Coolidge, Thomas R.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 12 pp., Cont.-in-part of U.S.  
 Ser. No. 851,738.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

US 2003073626	A1	20030417	US 2002-91258	20020305
US 6284725	B1	20010904	US 1999-302596	19990430
US 2002055460	A1	20020509	US 2001-851738	20010509
PRIORITY APPLN. INFO.:			US 1999-302596	A3 19990430
			US 2001-851738	A2 20010509
			US 1998-103498P	P 19981008

AB The present invention relates to methods of treating **intermittent claudication** comprising administering **glucagon-like peptide-1 (GLP-1)** mols. to subjects suffering therefrom. A method of treating or preventing skeletal muscle injury caused by ischemia and/or reperfusion in a subject comprising the step of administering a therapeutically effective amount of GLP-1 mol. is also claimed. The subject can also be administered free radical scavengers, glucose, or potassium. The GLP-1 compound is administered by an infusion pump or by s.c. injection of a slow-release formulation.

L69 ANSWER 2 OF 14 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

ACCESSION NUMBER: ADB84200 peptide DGENE

TITLE: Method for the treatment or prevention of **intermittent claudication** or skeletal muscle injury caused by ischemia and/or reperfusion in a human subject, comprises administration of a **glucagon-like peptide-1** molecule.

INVENTOR: Hathaway D R; Coolidge T R

PATENT ASSIGNEE: (HATH-I)HATHAWAY D R.

(COOL-I) COOLIDGE T R.

PATENT INFO: US 2003073626 A1 20030417 12p

APPLICATION INFO: US 2002-91258 20020305

PRIORITY INFO: US 1999-302596 19990430

US 2001-851738 20010509

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2003-677986 [64]

DESCRIPTION: Glucagon-like peptide-1, GLP-1(7-36).

AN ADB84200 peptide DGENE

AB The invention describes a method for the treatment or prevention of **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject, comprising the administration of a **glucagon-like peptide -1 (GLP-1)** molecule. The method is useful for treating or preventing **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject suffering from **peripheral vascular disease** (PVD). Administration of **GLP-1** in a subject improves skeletal muscle performance by promoting glucose oxidation and reducing fatty acid oxidation. This is the amino acid sequence of a mammalian **glucagon-like peptide -1 peptide GLP-1(1-37)** that can be used in the method of the invention.

L69 ANSWER 3 OF 14 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

ACCESSION NUMBER: ADB84202 peptide DGENE

TITLE: Method for the treatment or prevention of **intermittent claudication** or skeletal muscle injury caused by ischemia and/or reperfusion in a human subject, comprises administration of a **glucagon-like peptide-1** molecule.

INVENTOR: Hathaway D R; Coolidge T R

PATENT ASSIGNEE: (HATH-I)HATHAWAY D R.

(COOL-I) COOLIDGE T R.

PATENT INFO: US 2003073626 A1 20030417 12p

APPLICATION INFO: US 2002-91258 20020305

PRIORITY INFO: US 1999-302596 19990430

US 2001-851738 20010509

DOCUMENT TYPE: Patent  
LANGUAGE: English  
OTHER SOURCE: 2003-677986 [64]  
DESCRIPTION: Glucagon-like peptide-1, GLP-1(9-36).

AN ADB84202 peptide DGENE

AB The invention describes a method for the treatment or prevention of **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject, comprising the administration of a **glucagon-like peptide -1 (GLP-1)** molecule. The method is useful for treating or preventing **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject suffering from **peripheral vascular disease** (PVD). Administration of **GLP-1** in a subject improves skeletal muscle performance by promoting glucose oxidation and reducing fatty acid oxidation. This is the amino acid sequence of a mammalian **glucagon-like peptide -1 peptide GLP-1(1-37)** that can be used in the method of the invention.

L69 ANSWER 4 OF 14 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

ACCESSION NUMBER: ADB84201 peptide DGENE

TITLE: Method for the treatment or prevention of **intermittent claudication** or skeletal muscle injury caused by ischemia and/or reperfusion in a human subject, comprises administration of a **glucagon-like peptide-1** molecule.

INVENTOR: Hathaway D R; Coolidge T R

PATENT ASSIGNEE: (HATH-I)HATHAWAY D R.

(COOL-I) COOLIDGE T R.

PATENT INFO: US 2003073626 A1 20030417 12p

APPLICATION INFO: US 2002-91258 20020305

PRIORITY INFO: US 1999-302596 19990430

US 2001-851738 20010509

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2003-677986 [64]

DESCRIPTION: Glucagon-like peptide-1, GLP-1(9-37).

AN ADB84201 peptide DGENE

AB The invention describes a method for the treatment or prevention of **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject, comprising the administration of a **glucagon-like peptide -1 (GLP-1)** molecule. The method is useful for treating or preventing **intermittent claudication** or skeletal muscle injury caused by ischaemia and/or reperfusion in a human subject suffering from **peripheral vascular disease** (PVD). Administration of **GLP-1** in a subject improves skeletal muscle performance by promoting glucose oxidation and reducing fatty acid oxidation. This is the amino acid sequence of a mammalian **glucagon-like peptide -1 peptide GLP-1(1-37)** that can be used in the method of the invention.



## WEST Search History





DATE: Tuesday, February 17, 2004

Hide?	<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Coun</u>
		<i>DB=PGPB,USPT,EPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L11	(GLP-1 or exendin-4 or glucagon adj like peptide adj 1) same treat\$ and atherosclerosis	1
<input type="checkbox"/>	L10	(GLP-1 or exendin-4 or glucagon adj like peptide adj 1) and ( treat\$ same atherosclerosis\$)	2
<input type="checkbox"/>	L9	(GLP-1 or exendin\$ or glucagon adj like peptide adj 1) and ( treat\$ same atherosclerosis\$)	2
<input type="checkbox"/>	L8	(GLP-1 or exendin\$ or glucagon adj like peptide adj 1) same treat\$ same atherosclerosis\$	
<input type="checkbox"/>	L7	(GLP-1 or exendin\$ or glucagon adj like peptide adj 1) same treat\$ atherosclerosis\$	
<input type="checkbox"/>	L6	(GLP-1 or exendin\$ or glucagon adj like peptide adj 1) same treat\$ same atherosclerosis	
<input type="checkbox"/>	L5	(GLP-1 or exendin\$ or glucagon adj like peptide adj 1) and (treat\$ same atherosclerosis )	2
<input type="checkbox"/>	L4	(GLP-1 or exendin\$ or glucagon adj like peptide adj 1) and (treat\$ same atherosclerosis or intermoittent adj claudication)	2
<input type="checkbox"/>	L3	(GLP-1 or exendin\$ or glucagon adj like peptide adj 1) and (atherosclerosis or intermoittent adj claudication)	2
<input type="checkbox"/>	L2	(GLP-1 or exendin\$ or glucagon adj like peptide adj 1) same (atherosclerosis or intermoittent adj claudication)	
<input type="checkbox"/>	L1	(GLP-1 or exendin\$ or glucagon adj like peptide adj 1) same (atherosclerosis same related or intermoittent adj claudication)	

END OF SEARCH HISTORY



## WEST Search History





DATE: Tuesday, February 17, 2004

Hide?	Set Name	Query	Hit Count
		<i>DB=PGPB,USPT,EPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L16	(GLP-1 or exendin-4 or glucagon adj like peptide adj 1) and ( peripheral adj vascular adj disease )	
<input type="checkbox"/>	L15	(GLP-1 or exendin-4 or glucagon adj like peptide adj 1) same ( peripheral adj vascular adj disease )	
<input type="checkbox"/>	L14	(GLP-1 or exendin-4 or glucagon adj like peptide adj 1) same ( treat\$ same ( atheroscleros\$ or atherosclerotic ))	
<input type="checkbox"/>	L13	(GLP-1 or exendin-4 or glucagon adj like peptide adj 1) and ( treat\$ same ( atheroscleros\$ or atherosclerotic ))	2
<input type="checkbox"/>	L12	hathaway-david-r\$.in.	
<input type="checkbox"/>	L11	(GLP-1 or exendin-4 or glucagon adj like peptide adj 1) same treat\$ and atherosclerosis	1
<input type="checkbox"/>	L10	(GLP-1 or exendin-4 or glucagon adj like peptide adj 1) and ( treat\$ same atheroscleros\$)	2
<input type="checkbox"/>	L9	(GLP-1 or exendin\$ or glucagon adj like peptide adj 1) and ( treat\$ same atheroscleros\$)	2
<input type="checkbox"/>	L8	(GLP-1 or exendin\$ or glucagon adj like peptide adj 1) same treat\$ same atheroscleros\$	
<input type="checkbox"/>	L7	(GLP-1 or exendin\$ or glucagon adj like peptide adj 1) same treat\$ atheroscleros\$	
<input type="checkbox"/>	L6	(GLP-1 or exendin\$ or glucagon adj like peptide adj 1) same treat\$ same atherosclerosis	
<input type="checkbox"/>	L5	(GLP-1 or exendin\$ or glucagon adj like peptide adj 1) and (treat\$ same atherosclerosis )	2
<input type="checkbox"/>	L4	(GLP-1 or exendin\$ or glucagon adj like peptide adj 1) and (treat\$ same atherosclerosis or intermoittent adj claudication)	2
<input type="checkbox"/>	L3	(GLP-1 or exendin\$ or glucagon adj like peptide adj 1) and (atherosclerosis or intermoittent adj claudication)	2
<input type="checkbox"/>	L2	(GLP-1 or exendin\$ or glucagon adj like peptide adj 1) same (atherosclerosis or intermoittent adj claudication)	
<input type="checkbox"/>	L1	(GLP-1 or exendin\$ or glucagon adj like peptide adj 1) same (atherosclerosis same related or intermoittent adj claudication)	

END OF SEARCH HISTORY